AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in adolescents aged 10–17 with type 2 diabetes in a late-stage study, the UK-based drugmaker said.
https://www.pharmalive.com/wp-content/uploads/2021/06/AstraZeneca’s-Lynparza-reduces-relapse-death-in-breast-cancer-patients-Reuters-6-4-21.jpg503960Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-06-25 17:49:082021-06-28 12:55:09AstraZeneca’s diabetes drug study shows benefit in adolescents